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Abstract
Background: The purpose of the present study was to determine how acute adult and/or prior early-in life (EIL;
P14-P16) exposure to bladder inflammation affects bladder content of calcitonin gene related peptide (CGRP) and
substance P (SP). Estrous cycle influences were also studied in the adult-treatment conditions.
Methods: In Experiment 1, intravesical zymosan or isoflurane anesthesia alone was administered to adult female
rats. Bladders and serum were collected 24 hours later during each phase of the estrous cycle. In Experiment 2,
zymosan or anesthesia alone was administered EIL and as adults, with bladder tissue collection 24 h later.
Results: In general, Experiment 1 showed that bladder content of both CGRP and SP was increased by
inflammation. This effect was significant when data were collapsed across all phases of the estrous cycle, but was
only significant during proestrus when individual comparisons were made during each phase of estrous. Also, adult
bladder inflammation significantly reduced estradiol levels. In Experiment 2, bladder content of CGRP and SP was
significantly increased in rats receiving EIL and/or adult inflammation. Bladder weights were also significantly
increased by inflammation.
Conclusions: These data indicate that bladder CGRP and SP are maximally increased during the proestrus phase of
the estrous cycle in inflamed adult female rats. EIL exposure to bladder inflammation alone can also produce an
increase in CGRP and SP lasting into adulthood. Therefore, EIL experience with bladder inflammation may
predispose an organism to experience a painful bladder disorder as an adult by increasing primary afferent content
of CGRP and/or SP.
Background
The mechanisms underlying bladder hypersensitivity
arising from bladder inflammation have been examined
by various investigators through the use of agents such as
cyclophosphamide (CYP) [1-4], zymosan [5,6], turpentine
[7] and mustard oil [8,9]. These studies indicate that
bladder tissue, dorsal root ganglion (DRG), and spinal
cord content [1,5,8] of two of the primary neurotransmit-
ters of bladder afferents, calcitonin gene-related peptide
(CGRP) and substance P (SP), increase following bladder
inflammation and may play a critical role in mediating
inflammation-produced bladder hypersensitivity. Func-
tional measures indicate that bladder hypersensitivity is
affected by several factors such as the phase of the
estrous cycle or the phase of the menstrual cycle in
which bladder sensitivity is tested [10,11]. For example,
the vigor of the visceromotor reflex (VMR) to urinary
bladder distension (UBD) in inflamed female rats is ele-
vated in proestrus relative to controls [6]. In humans, the
highest daily “worst pain” scores in women with IC occur
during the premenstrual period and urinary symptoms
increase in the perimenstrual period [12,13]. In addition
to estrous cycle influences, bladder hypersensitivity
resulting from bladder inflammation as an adult can be
enhanced further by prior early-in-life (EIL; P14-P16)
experience with bladder inflammation [14,15], and this
experimental paradigm has been advanced as a possible
model for studying the etiology of painful bladder syn-
drome/interstitial cystitis (PBS/IC). However, at the pre-
sent time, it is not known whether these findings based
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any medium, provided the original work is properly cited.on functional measures relate in any way to bladder levels
of CGRP and SP and so serves as the focus of the present
investigations.
The goal of Experiment 1 was to determine whether
adult bladder content of CGRP and SP was affected by
estrous cycle and either the presence or absence of acute
bladder inflammation. The goal of Experiment 2 was to
evaluate how an EIL episode with bladder inflammation
affected adult bladder content of CGRP and SP either
with or without additional adult bladder inflammation.
Methods
Animals
In Experiment 1, 12 week old adult female Sprague-Daw-
ley rats were obtained as adults from Harlan. For Experi-
ment 2, timed-pregnant female Sprague-Dawley rats
were obtained from Harlan and pups were born and
raised in our facilities. All animals were 12-14 weeks old
at the time of testing. The light-dark cycle for all rats was
6:00 am - 6:00 pm. All studies were approved by the Uni-
versity of Alabama at Birmingham Animal Care and Use
Committee, and conformed to the guidelines of the Inter-
national Association for the Study of Pain (IASP).
Lavage
The stage of estrous was determined by daily vaginal
lavages beginning at approximately 12 weeks of age.
Each rat had to show at least two complete cycles prior
to treatment. Estrous determination was as described by
Becker et al. [16] where: metestrus- composed mainly of
leukocytes with few nucleated and/or cornified cells,
diestrus- lacking or nearly lacking the presence of all
cells, proestrus- composed mainly of nucleated cells,
and estrus- composed mainly of cornified cells.
ELISA and RIA
At the time of sacrifice, all rats were deeply anesthetized
under isoflurane anesthesia (5%). Bladders were removed
from all rats and cardiac blood was collected from all rats
in the acute, adult conditions. Serum was centrifuged at
1600 rpm for 15 min and stored at -80°C until analyzed.
The urinary bladder from each rat was flash-frozen in
liquid nitrogen, then stored at -80°C. Bladders were ana-
lyzed for SP and CGRP using ELISAs (Phoenix Pharma-
ceuticals, Burlingame, CA). Progesterone and estradiol
levels were determined with radioimmunoassays (RIAs) by
t h eU n i v e r s i t yo fV i r g i n i aC e n t e rf o rR e s e a r c hi nR e p r o -
ductive Ligand Assay and Analysis Core. However, all
group assignments were based on vaginal lavages and not
hormone levels.
Acute Adult inflammation
In Experiment 1, rats were designated into either
anesthesia-alone pretreatment or zymosan pretreatment.
Zymosan pretreated rats were anesthetized with isoflur-
ane/oxygen (5% induction/2% maintenance) and a 22-
gauge angiocatheter was placed into the urinary bladder
via the urethra. Intravesical zymosan (1% solution in sal-
ine; 0.5 ml) was administered and left to dwell for 30
min before draining and catheter removal. This dose/
concentration of zymosan has been previously shown to
produce bladder inflammation using the testing para-
meters of this study [17]. The anesthesia-alone pre-
treated rats were given only isoflurane anesthesia for 30
min. Each rat was administered s.c. ampicillin after the
procedure (200 mg) and awakened. This resulted in two
conditions or groups: group A (anesthesia alone) and
group Z (zymosan). Anesthesia-alone controls were used
in these experiments and not naïve rats because
anesthesia involving volatile anesthetics, e.g. halothane
versus isoflurane, is known to have markedly different
influences on a wide variety of measures of nociception
including c-fos expression [18] and first order dorsal
horn neurons [19,20] and so they were appropriate con-
trols for the inflamed groups which were also anesthe-
tized with isoflurane.
Group assignment was based on the phase of the estrous
cycle the animal was in at the time of testing based on
vaginal lavage. We pretreated all rats between 5-6 pm 24 h
prior to sacrifice. We did this because progesterone and
estrogen have been reported to be closest to their peak
levels at 5-6 pm in the proestrus phase [21]. We wanted to
maximize the likelihood of observing high levels of these
hormones to increase our ability to detect differences
between anesthesia-alone and zymosan-treated animals.
We also wanted to keep the time of day of both pretreat-
ment and bladder tissue harvesting constant.
EIL
In Experiment 2, on each day from P14-P16, female rat
pups were halothane-anesthetized (5% induction, 1-2%
maintenance) via mask, had their urethras swabbed with
iodine-povidone solution, and were kept warm with a
heating pad. On each day, zymosan-treated groups had a
24-gauge angiocatheter placed transurethrally into the
urinary bladder and received intravesical administration of
0.10 ml of zymosan (1% in saline) for 30 min. The
anesthesia-alone groups were anesthetized for 30 min but
had no intravesical catheter placement or treatment. All
rats were given ampicillin (20 mg/kg, s.c.) on each treat-
ment day. An intravesical saline group was not examined
as previous studies demonstrated no physiologically
important differences between saline-treated groups and
those treated with anesthesia alone [15].
As adults, these rats received either anesthesia-alone
pretreatment or zymosan pretreatment as described
above. This resulted in four conditions or groups: group
AA (anesthesia alone EIL and anesthesia alone as adult),
Shaffer et al. BMC Urology 2011, 11:18
http://www.biomedcentral.com/1471-2490/11/18
Page 2 of 8group AZ (anesthesia alone EIL and zymosan as adult),
group ZA (zymosan EIL and anesthesia as adult), and
group ZZ (zymosan EIL and zymosan as adult).
Statistics
All data are presented as group mean ± standard error of
the mean (SEM). Overall ANOVAs were performed and
followed by post-hoc t-tests as appropriate (a = 0.05).
Holm’s correction was used for multiple comparisons.
Results
Acute adult inflammation - Anesthesia Alone and
Zymosan Conditions
CGRP and SP
Figure 1 presents group mean CGRP and SP levels for
anesthesia-alone (open bars) and zymosan-inflamed (solid
bars) groups during each phase of estrous and the insets
show group mean levels of these peptides collapsed across
all phases of estrous. An overall ANOVA revealed a signif-
icant effect of intravesical treatment on bladder content of
CGRP (F(1,38) = 4.64, p < 0.03) but no significant effect of
estrous cycle or estrous cycle × treatment interaction. In
general, CGRP content was increased by inflammation
and it was significantly greater in the inflamed condition
when data from all rats were collapsed across all phases of
the estrous cycle as shown in the inset (p = 0.04). Indivi-
dual estrous phase-matched comparisons between zymo-
san and anesthesia-alone groups, however, revealed that
CGRP levels were significantly greater in zymosan-treated
rats only during proestrus (p = 0.04).
An overall ANOVA revealed a significant effect of
intravesical treatment group on bladder content of SP
( F ( 1 , 3 9 )=6 . 0 6 ,p=0 . 0 2 )a n das i g n i f i c a n te f f e c to f
estrous cycle (F(3,39) = 2.92, p = 0.05). In general,
groups treated with zymosan showed greater levels of
SP than estrous-phase matched anesthesia controls and
SP content was significantly greater in inflamed rats
when data were collapsed across all phases of the
estrous cycle as shown in the inset (p = 0.02). Similar
to the CGRP data, individual estrous phase-matched
comparisons between zymosan and anesthesia-alone
groups revealed that SP levels were significantly greater
in zymosan-treated rats only during proestrus (p =
0.01). In addition, there was a clear trend for both
CGRP and SP levels to increase in zymosan-treated
groups as animals progressed through the estrous cycle
from estrus to proestrus. In contrast, no such trend was
observed in anesthesia-alone groups.
Bladder Weights
Bladder weights for Experiment 1 are shown in the bot-
tom panel of Figure 2. Bladder weights did not signifi-
cantly vary as a function of the phase of the estrous cycle
when comparisons were made within either the anesthe-
sia-alone condition (F(3,21) = 1.98; p = 0.14) or the
zymosan condition (F(3,20) = 0.55; p = 0.65). However,
bladder weights of zymosan-treated rats were signifi-
cantly greater than those treated with anesthesia alone (F
(1,41) = 15.01; p < 0.01) and post-hoc comparisons indi-
cated bladders of zymosan-treated rats were significantly
increased in both diestrus (p < 0.01) and proestrus (p <
0.01) relative to anesthesia controls. To calculate bladder
content of CGRP and SP, the concentration of peptide in
each sample, measured using ELISA, was multiplied by
the weight of each bladder. Therefore, bladder content of
CGRP and SP was proportional to bladder weight, and
increased bladder weights were associated with increased
CGRP and SP levels. However, neither CGRP nor SP was
Figure 1 Figure 1 presents mean group bladder content of CGRP (ng) and SP (pg) during each phase of the estrous cycle in animals
treated with either anesthesia (open bars) or zymosan (solid bars) (n = 6-7 rats/group). The insets show data for all rats collapsed across
phases of the estrous cycle. Error bars depict standard error of the mean (SEM). CGRP and SP were significantly increased by adult zymosan
treatment during proestrus as well as when data were collapsed across phases of the estrous cycle (* significantly different from anesthesia
control p < 0.05).
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weights were significantly increased in inflamed rats rela-
tive to control rats. These data indicate that while blad-
der weight increases may be a necessary condition for
increased CGRP and SP levels, bladder weight alone is
not a sufficient condition to produce these increases.
Estradiol and progesterone
The top panel of Figure 2 shows that zymosan-treated rats
had consistently lower levels of estradiol compared to
anesthesia-alone controls. This lowering was significant
when data were collapsed across all phases of estrous
(F(1,30) = 4.52; p = 0.04) but not when data were com-
pared during any specific phase of estrous. The middle
panel of Figure 2 shows that progesterone levels also
tended to be reduced by zymosan but no significant reduc-
tions were found. In general, the data suggest that inflam-
mation and/or anesthesia-alone produced some disruption
in the normal levels of these hormones that would be
expected on the basis of other reports that have examined
levels of these hormones in normal cycling naive rats, (e.g.,
[21]), but as noted previously, classification was done on
the basis of vaginal lavage at the time of testing.
EIL bladder inflammation
CGRP and SP
Bladder content of CGRP in EIL-treated animals is shown
in the upper panel of Figure 3 from Experiment 2. An
overall ANOVA revealed a significant effect of intravesical
treatment on bladder content of CGRP (F(3,19) = 19.01,
p < 0.01). Follow-up comparisons revealed that all treat-
ments significantly increased bladder content of CGRP
compared to AA controls. Specifically, bladder content of
CGRP in AZ (p < 0.01), ZA (p = 0.01), and ZZ (p < 0.01)
animals was significantly greater than that of AA controls.
Also, re-inflammation as an adult significantly increased
bladder content of CGRP since bladder content of CGRP
was significantly greater in ZZ animals compared to ZA
animals (p < 0.01). There was a trend indicating that prior
EIL inflammation may have increased bladder content of
CGRP in animals re-inflamed as adults since bladder con-
tent of CGRP was also greater in ZZ animals compared to
AZ animals (p = 0.03), but this comparison was non-sig-
nificant after correcting for multiple comparisons.
An overall ANOVA revealed a significant effect of intra-
vesical treatment group on bladder content of SP (F(3,19)
= 5.78, p < 0.01). Follow-up comparisons revealed that all
treatments significantly increased bladder content of SP
compared to AA controls. Specifically, bladder content of
SP in AZ, ZA, and ZZ animals was significantly greater
than that of AA controls (all p’s<0 . 0 1 ) .
The absolute levels of CGRP and SP differed between
Experiments 1 and 2, but groups did not receive identical
treatments in these experiments. Further, such differ-
ences may reflect different housing conditions encoun-
tered by these animals during maturation. Animals in
Experiment 1 were acquired from Harlan at 12 weeks of
Figure 2 Group mean estradiol levels (pg/ml), progesterone
levels (ng/ml), and bladder weights (g) for each phase of the
estrous cycle in animals treated with either anesthesia (open
bars) or zymosan (solid bars) (n = 6-7 rats/group). Error bars depict
standard error of the mean (SEM). Estradiol levels were significantly
decreased by adult zymosan treatment when data were collapsed
across phases of the estrous cycle. Bladder weights were significantly
decreased by adult zymosan treatment during diestrus and proestrus,
as well as when data were collapsed across phases of the estrous cycle
(* significantly different from anesthesia control p < 0.05).
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in our animal housing facilities.
Bladder Weights
Bladder weights for Experiment 2 are shown in Table 1.
An overall ANOVA revealed a significant effect of intra-
vesical treatment group on bladder weights (F(3,35) =
12.18, p < 0.01). Post-hoc comparisons indicated that all
groups receiving zymosan had significantly greater blad-
der weights than group AA as would be expected to
occur following inflammation (all p’s < 0.03). Interest-
i n g l y ,t h ed a t af r o mg r o u pZ Ai n d i c a t et h a ta nE I L
exposure to bladder inflammation alone is a sufficient
condition to produce a permanent increase in bladder
weight that lasts into adulthood. Also, the increase pro-
duced by EIL and adult treatment combined (group ZZ)
was greater than that produced by EIL inflammation
(group ZA; p < 0.01) or adult inflammation alone
(group AZ; p = 0.01).
Discussion
The effect of estrous cycle on bladder content of CGRP
and SP after acute adult bladder inflammation
Pain arising from bladder disorders is a common problem
in women and some of these pain disorders are hypothe-
sized to result from increases in the content of CGRP and
SP in the bladder with consequent sensitization of bladder
afferents containing these neuropeptides. Double-labeling
studies in human bladder indicate that approximately 26%
of CGRP-immunoreactive fibers contain SP [8,22]. In rat,
approximately 40-54% of L6-S1 DRG bladder afferent cells
express CGRP, whereas only approximately 2-3% of L6-S1
DRG bladder afferent cells express SP-IR, and virtually all
SP-IR fibers contain CGRP [1], see also [23]. In male rats,
CGRP- and SP-IR are increased in the DRG of bladder
afferent neurons and the spinal cord following acute blad-
der inflammation with mustard oil [8]. A similar outcome
has been obtained in female rats using chronic bladder
inflammation with CYP, which significantly increases
CGRP-IR in the L6 DRG, but not the S1 DRG. Increases
in SP-containing nerve fibers in the submucosal region
[24] and increased levels of NK1 receptor encoding
mRNA in the vascular endothelium [23] also have been
reported in biopsies obtained from IC patients. None of
the above studies, however, have systematically examined
influences of the estrous or menstrual cycles on measures
of CGRP and SP or other factors such as EIL experience
with bladder inflammation, which could serve as impor-
tant contributing factors in exacerbating pain.
Experiment 1 of the present studies examined bladder
content of CGRP and SP during each phase of the
estrous cycle in acutely-inflamed adult rats. Both CGRP
and SP were significantly increased after inflammation
during the proestrus phase of estrous when compared to
estrous phase-matched anesthesia-alone controls. Similar
matched comparisons in the other phases of estrous were
not significant although the bladder content of both
CGRP and SP was significantly increased when data from
all acutely-inflamed rats were collapsed across all phases
of the estrous cycle. These data support the view that if
CGRP and/or SP mediate bladder hypersensitivity then
hypersensitivity is likely to be maximal during proestrus
Figure 3 Figure 3 presents group mean bladder content of CGRP
(ng) and SP (pg) in rats treated EIL. Error bars depict standard error
of the mean (SEM). Rats were treated with either anesthesia both EIL
and as adults (AA), anesthesia EIL and zymosan as adults (AZ), zymosan
EIL and anesthesia as adults (ZA), or zymosan both EIL and as adults
(ZZ) (n = 4-7 rats/group). Groups AZ, ZA, and ZZ differed significantly
from group AA for both CGRP and SP (* significantly different from
anesthesia control p < 0.05). CGRP for group ZZ also was significantly
increased relative to ZA animals (+ p < 0.01).
Table 1 Group mean bladder weights (mg ± SEM) for the
groups of Experiment 2
Group AA AZ ZA ZZ
Bladder Weight 69.0 ± 13
2 114.0 ± 2
12 98.5 ± 13
12 145.5 ± 9
1
Rats were treated with either anesthesia both EIL and as adults (AA),
anesthesia EIL and zymosan as adults (AZ), zymosan EIL and anesthesia as
adults (ZA), or zymosan both EIL and as adults (ZZ) (n = 4-7 rats/group).
Bladder weights were significantly greater in AZ, ZA, and ZZ animals
compared to AA controls. In addition, the bladders of ZZ animals were also
significantly heavier than those of AZ and ZA animals.
1 significantly different from AA (p < 0.05)
2 significantly different from ZZ (p < 0.05)
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findings by other investigators showing that response
thresholds for the VMR to UBD were lowest during
proestrus [25] and mean response thresholds of pelvic
mechanoreceptors innervating the bladder and mean
bladder compliance are lowest in proestrus in adult
female urethane-anesthetized rats [26]. These data also
correspond reasonably well to recently reported data
showing that adult female rats with zymosan-induced
bladder inflammation had the most robust VMRs to
UBD during metestrus and proestrus [6]. In the present
study, we did not observe significant increases in these
peptides during metestrus.
We observed no significant differences in CGRP and
SP levels as a function of the phase of estrous cycle in
rats that did not have inflamed bladders. This outcome
bears similarity to a previous study that found no signif-
icant differences in the magnitude of the VMR to UBD
as a function of the phase of estrous cycle in adult
female rats with non-inflamed bladders [6] and are ana-
logous to the lack of estrous cycle effects observed by
Johnson and Berkley [7] in female rats with non-
inflamed bladders undergoing analyses of micturition
response thresholds in cystometrogram (CMG) testing.
Therefore, the effects of estrous cycle are most clearly
manifested under conditions of bladder inflammation.
Bladder content of CGRP and SP in animals with or
without EIL bladder inflammation and adult re-
inflammation
Experiment 2 examined bladder content of CGRP and
SP after an EIL exposure to bladder inflammation. EIL
inflammation produced an increase in CGRP and SP
bladder content that lasted into adulthood and was
comparable to that produced by an acute, adult expo-
sure to bladder inflammation (compare groups ZA and
group AZ in Figure 3). Since increased bladder weights
were associated with increases in CGRP and SP in both
experiments, we evaluated the extent to which the
increases in CGRP and SP were dependent on increased
bladder weight. While increased bladder weights may
well have contributed to the increased levels of these
bladder peptides in both Experiments 1 and 2, two
points should be noted. First, if bladder weights are cri-
tical for increasing the levels of these peptides then they
are only a necessary condition and not a sufficient con-
dition for this to occur. That is, significant bladder
weight increases were observed in rats with inflamed
bladders during diestrus in Experiment 1, but we
observed no significant increases in CGRP and SP levels
during diestrus. Second, even when we controlled for
the increased bladders weights of inflamed rats exam-
ined in Experiment 2, by examining the content per mg
of bladder tissue, we still observed significant increases
in CGRP and SP in groups AZ, ZA, and ZZ relative to
group AA.
The issue of bladder weight is important, however,
because heavier and presumably larger bladders contain-
ing more neuropeptides in the absence of other changes
in the nervous system may functionally translate into
greater input into the spinal cord and enhanced bladder
sensitivity. At a minimum, these data support the view
that an EIL experience with bladder inflammation may
potentially predispose an organism to experience a pain-
ful bladder disorder as an adult if it is mediated by CGRP
and/or SP especially when followed by re-exposure to
bladder inflammation as an adult.
Some studies suggest that CGRP and SP act synergisti-
cally [27-30] due to CGRP inhibition of an endopeptidase
which degrades SP [31]. Thus, SP may be the primary neu-
rotransmitter that enhances spinal nociceptive transmis-
sion under conditions of bladder inflammation during
proestrus and CGRP may act as a neuromodulator serving
to facilitate the spinal activity of SP at this time. One must
also entertain the possibility that similar interactions
between CGRP and SP could occur peripherally in the
bladder to influence bladder afferent sensitivity in some
manner.
Gonadal Hormones
In studies of acute, adult inflammation (Experiment 1), we
observed that bladder inflammation generally reduced
estradiol levels during all phases of estrous and the levels
were significantly lower than those of anesthesia-alone
controls when collapsed across all phases of estrous. Pro-
gesterone levels also tended to be reduced by bladder
inflammation but these reductions were not statistically
significant. Finally, serum hormone levels indicated disrup-
tion in normal gonadal cycling due to inflammation and/
or isoflurane anesthesia despite the fact that animals
showed normal vaginal lavages and were therefore classi-
fied solely on that basis.
Evidence concerning whethere s t r o g e na n d / o rp r o g e s -
terone either increase or decrease pain sensitivity is con-
troversial. There is evidence for antinociceptive effects of
estrogen in somatic pain models involving hot plate and
tail withdrawal responses [11], phase 2 of the formalin
test [32,33], and in slow developing mechanical and ther-
mal hyperalgesia of the abdominal and pelvic muscles
produced by ovariectomy (OVX) [34]. However, the
opposite outcome has been observed in other studies of
visceral nociceptive systems. In these studies, OVX
reduced VMRs to UBD [35] and to colorectal distension
[36] and the acute replacement of estrogen in these
model systems produced increases in VMRs [37,38]. In
mice, the presence of estrogen receptor-alpha effects in
the absence of estrogen receptor-beta effects results in
histological alterations of the bladder reminiscent of
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ferences in estrogen effects, perhaps involving differential
activation of estrogen receptor-alpha and beta that con-
tribute to contrasting pro- and anti-nociceptive effects in
different tissues.
Interestingly, we have previously observed that rapidly
falling levels of estrogen are associated with an augmen-
tation of the VMRs [38]. Therefore a sudden change in
circulating estrogen, rather than a sustained increase (as
during prolonged hormone replacement) or decrease (as
during testing several days after OVX), may lead to
increased responses to visceral nociceptive stimuli. In the
context of the present experiment, and using similar
parameters, it is notable that inflammation resulted in a
general drop in estrogen levels. A drop in estrogen per-
haps could contribute to the augmentation of VMRs
observed in other studies and also could account for the
general tendency to observe increases in CGRP and SP
levels across all phases of the estrous cycle in the present
study by promoting CGRP and SP synthesis.
Clinical Relevance
The clinical relevance of these basic science findings and
our EIL animal model relate to chronic pain disorders,
such as PBS/IC. As noted in previous studies, c.f. [15] this
EIL animal treatment results in increased micturition fre-
quency, bladder hypersensivity, and decreased intercon-
traction intervals during CMG testing which parallel
human PBS/IC symptoms of increased urinary frequency,
bladder pain, and urgency. Our EIL animal model also has
been shown to mimic outcomes of a human clinical study
by Mukerji et al. [40] of PBS/IC patients. They found that
76.5% of female patients with PBS/IC reported pain during
an intravesical instillation of ice cold saline whereas
females with idiopathic detrusor overactivity (IDO), neuro-
genic detrusor overactivity (NDO), or normal controls did
not report pain during similar tests. As a form of reverse
translational research to test the validity of our EIL model,
we evaluated whether a similar cold sensitivity was present
in our rodent model system. When tested as adults, EIL
bladder inflammation resulted in significantly increased
VMRs to intravesical cold stimuli even in the absence of
re-inflammation as an adult [41].
Conclusions
The present studies demonstrate that CGRP and SP are
increased by adult bladder inflammation, and that EIL
exposure to bladder inflammation alone can also pro-
duce an increase in CGRP and SP lasting into adult-
hood. Phase of the estrous cycle also impacts bladder
CGRP and SP content; CGRP and SP are maximally
increased during the proestrus phase of the estrous
cycle in inflamed adult female rats. Increases in
endogenous CGRP and SP may translate into increased
spinal nociceptive transmission and enhanced bladder
sensitivity. Other studies from our laboratory also have
shown that descending inhibitory [6,14] and facilitatory
[42] pain modulatory systems are altered by bladder
inflammation, indicating that complex changes in pain
processing may occur at multiple points and these
changes may interact to produce chronic bladder pain.
The clinical relevance of this study includes the sugges-
tion that EIL experience with bladder inflammation may
be one of many possible factors that could predispose
an individual to experience a painful bladder disorder as
an adult by increasing primary afferent content of
CGRP and/or SP. In addition, this study suggests a pos-
sible physiological basis for alterations in bladder sensi-
tivity during the menstrual cycle.
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